Protagonist Therapeutics Price to Free Cash Flow Ratio 2015-2022 | PTGX

Historical price to free cash flow ratio values for Protagonist Therapeutics (PTGX) since 2015. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Protagonist Therapeutics Price to Free Cash Flow Ratio Historical Data
Date Stock Price TTM FCF per Share Price to FCF Ratio
2022-07-01 7.86 0.00
2022-03-31 23.68 $-2.48 0.00
2021-12-31 34.20 $-2.35 0.00
2021-09-30 17.72 $-2.38 0.00
2021-06-30 44.88 $-2.16 0.00
2021-03-31 25.90 $-2.20 0.00
2020-12-31 20.16 $-2.12 0.00
2020-09-30 19.55 $-2.05 0.00
2020-06-30 17.66 $-2.22 0.00
2020-03-31 7.06 $-1.53 0.00
2019-12-31 7.05 $-1.64 0.00
2019-09-30 12.01 $-1.54 0.00
2019-06-30 12.11 $-1.37 0.00
2019-03-31 12.57 $-2.22 0.00
2018-12-31 6.73 $-2.26 0.00
2018-09-30 10.29 $-2.60 0.00
2018-06-30 6.72 $0.10 69.06
2018-03-31 8.59 $0.07 114.84
2017-12-31 20.80 $0.18 114.79
2017-09-30 17.67 $-1.21 0.00
2017-06-30 11.31 $-6.03 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.382B $0.027B
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease, a GI disease consisting primarily of ulcerative colitis and Crohn's disease; PTG-300, an injectable hepcidin mimetic. Protagonist Therapeutics, Inc. is based in Milpitas, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00